Josh Elias received his Ph.D. from Harvard Medical School in cell biology with Stephen Gygi. During his thesis research, Elias developed the now ubiquitous “target-decoy” search strategy for controlling proteomic experimental error. This effort established his long-standing interest in improving proteomics workflows, bringing them in sync with the robust methods used in genomics and allied fields. As a faculty member at Stanford University, Elias focused on solving three extraordinary challenges in proteomics: identifying disease-relevant antigens presented on MHC complexes; characterizing the biologically relevant proteins that mediate host-microbiome interaction, and improving methods for searching the vast sequence space these experiments encompass. At CZ Biohub SF, Elias leads the Mass Spectrometry platform; he and his team are expanding these efforts by making a deliberate effort to integrate multi-omic strategies — minimally proteomics and metabolomics — whenever possible. The technologies they are developing are broadly applicable, including methods to quantify dynamic post-translational regulation mechanisms that have so far been hidden in the “dark matter” of biology — molecules invisible to genomic technologies and standard proteomic assays.
Josh Elias, Ph.D.
Platform Leader
GET CZ BIOHUB NETWORK UPDATES IN YOUR INBOX
Subscribe to our bimonthly Nexus newsletter, and receive other updates from CZ Biohub Network.
Marketing cookies are required to access this form.